TT-232| ChemScene
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[2].In Vitro:TT-232 (10 μg/mL, 48 h) induces apoptosis in human colon (HT-29 and SW620), pancreatic (818), leukemia (K-562), melanoma (WM 938/B, M-1 and EP) and lymphoma (HT-58) tumor cell lines.
TT-232 (20-30 μg/mL, 24 h) shows antiproliferative effect on various human tumor cell lines[2].
In Vivo:TT-232 (15-750 μg/kg/day, twice a day) inhibits tumor growth in mice transplanted with Colon 26 cell[2].
TT-232 (0.6 or 15 μg/kg s.c or i.p.) shows antitumor effect on P-388 rodent lymphocytic leukemia tumor mice.
TT-232 (7.5-20 μg/kg, i.v.) inhibits Carrageenin-induced paw oedema in rats.
Trivial name | TT-232 |
Catalog Number | CS-0025194 |
Alternative Name(s) | CAP-232; TLN-232 |
Molecular Formula | 947.13 |
CAS# | 147159-51-1 |
Purity | >98% |
Condensed Formula | C45H58N10O9S2 |
Size | 1mg |
Supplier Page | www.chemscene.com/147159-51-1.html |